. 2011 Mar 17;32(8):963–971. doi: 10.1093/eurheartj/ehr091

Table 3.

Plasma levels of CXCL12 vary by single-nucleotide polymorphisms from genome-wide association studies of coronary artery disease/myocardial infarction in PennCath and PennCAC

SNP (study, RAF)	Published risk allele, OR for CAD/MI (P-value)	Plasma CXCL12 levels by number of risk alleles in PennCath	Plasma CXCL12 levels by number of risk alleles in PennCAC
rs501120 (WTCCC, 0.87; PennCath, 0.87; PennCAC, 0.86)	T, 1.33 (10⁻⁸)^a	TT^ï (n = 874) 2.34 ± 0.49	TT^‖ (n = 993) 2.52 ± 0.57
		TC^ï (n = 271) 2.28 ± 0.46	TC^‖ (n = 345) 2.49 ± 0.54
		CC^ï (n = 28) 2.23 ± 0.53	CC^‖ (n = 35) 2.41 ± 0.46

rs1746048^b (MIGEN, 0.86; PennCath, 0.87; PennCAC, 0.86)	C, 1.17 (10⁻⁹)^c	CC^¶ (n = 874) 2.33 ± 0.49	N/A
		CT^¶ (n = 276) 2.27 ± 0.46	N/A
		TT^¶ (n = 27) 2.21 ± 0.52	N/A

RAF, risk allele frequency.

^aData derived from Wellcome Trust Case Control Consortium and German MI Study.^1,2

^bBased on quantitative trait means for rs1632484, which has r² = 0.98 in PennCath and r² = 1.0 in HapMap with rs1746048. The allelic dosage effects are based upon rs1632484 because it was directly genotyped in PennCath, whereas rs501120 was imputed.

^cData derived from Myocardial Infarction Genetics Consortium Study.³

^ïP for trend = 0.038.

^‖P for trend = 0.005.

^¶P for trend = 0.036.